Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 12/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102920 | 0.90 | AURKA (0.50) | MAPTAURKAAURKBGSK3BSRC | |
| SCHEMBL2713578 | 0.88 | MEN1 (0.40) | MEN1KMT2AAURKAAURKBGSK3B | |
| SCHEMBL3324241 | 0.86 | AURKA (0.44) | MEN1KMT2AAURKAAURKBGSK3B | |
| SCHEMBL1532353 | 0.85 | AURKB (0.53) | AURKAAURKBGSK3BSRC | |
| SCHEMBL2957184 | 0.85 | MEN1 (0.40) | MAPTMEN1KMT2AAURKAAURKB | |
| SCHEMBL1078617 | 0.82 | AURKB (0.64) | AURKAAURKBGSK3BSRC | |
| SCHEMBL61333 | 0.81 | KMT2A (0.53) | MEN1KMT2AAURKAAURKBSMN1; SMN2 | |
| SCHEMBL1054549 | 0.81 | AURKA (0.53) | AURKAAURKBSRCNTRK1 | |
| SCHEMBL648099 | 0.80 | AURKA (0.58) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL1816236 | 0.80 | AURKB (0.55) | AURKAAURKBGSK3BSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779127-B2 | Processes for preparing substituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-14 | — | — | US | disclosed |
| US-8268829-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100120772-A1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-13 | — | — | US | disclosed |
| US-20090227598-A1 | Ret Tyrosine Kinase Inhibition | MERCK SHARP & DOHME CORP. | 2009-09-10 | — | — | US | disclosed |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009086012-A1 | AURORA INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2009063240-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF AURORA KINASE | ARROW THERAPEUTICS LIMITED (GB) | 2009-05-22 | — | — | WO | disclosed |
| US-20090105270-A1 | Kinase inhibition and anticancer therapy | BUSER-DOEPNER CAROLYN A | 2009-04-23 | — | — | US | disclosed |
| US-20060270660-A1 | inhibitors of FLT-3, Aurora-1, Aurora-2, and Aurora-3 protein kinases; leukemia; N-{4-[4-(5-Methyl-2H-pyrazol-3-ylmethyl)-6-(4-propyl-piperazin-1-yl)-pyrim- idin-2-ylsulfanyl]-phenyl}-propionamide | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227598-A1 | Ret Tyrosine Kinase Inhibition | RET, FER, TYRO3 | MAPT 2481/4885MEN1 487/4885KMT2A 292/4885 |
| US-20090105270-A1 | Kinase inhibition and anticancer therapy | MAP3K20, MAP3K10, MAP3K2 | MAPT 3044/4885MEN1 3576/4885KMT2A 1055/4885 |
| US-20060270660-A1 | inhibitors of FLT-3, Aurora-1, Aurora-2, and Aurora-3 protein kinases; leukemia; N-{4-[4-(5-Methyl-2H-pyrazol-3-ylmethyl)-6-(4-propyl-piperazin-1-yl)-pyrim- idin-2-ylsulfanyl]-phenyl}-propionamide | FLT3, AURKA, AURKC | MAPT 1559/4885MEN1 1824/4885KMT2A 251/4885 |
| US-20100120772-A1 | P38 KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | MAPT 1742/4885MEN1 4855/4885KMT2A 4492/4885 |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | MAPT 982/4885MEN1 1350/4885KMT2A 1235/4885 |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | MAPT 982/4885MEN1 1350/4885KMT2A 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.